Cardiff Oncology, Inc. (CRDF) analyst actions
Rating and price-target actions on CRDF in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CRDF overview →
1 measured CRDF analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 | Press release | -0.90% | +3.85% |
Keep exploring
More CRDF: earnings → · SEC filings → · CRDF overview →